Abstract 10039: Rise in Incidence of Takotsubo Syndrome, Associated Comorbidities and Major Adverse Cardiac and Cerebrovascular Events Among Cancer Survivors: A Nationwide Analysis of Two Cohorts a Decade Apart (2007 & 2017)

Abstract

Introduction: Studies in the last decade have shown an increased prevalence of Takotsubo syndrome (TTS); however, there is limited data on the prevalence and impact of TTS on hospitalizations among cancer survivors. Methods: We identified adult hospitalizations with prior cancer and TTS using National inpatient samples from 2007 & 2017. We then compared the demographics, comorbidities, and in-hospital outcomes between two cohorts 10-years apart. In addition, we also performed multivariable analysis to evaluate the composite outcomes of MACCE (all-cause mortality, cardiac arrest, arrhythmia and stroke) after adjusting for sociodemographic, type of admission, hospital characteristics, comorbidities, current cancer, and prior chemo/radiotherapy. Results: Prevalence of TTS per 100,000 hospitalizations among cancer survivors increased about 8-fold from 23 to 163 (p<0.001) between 2007 and 2017 (Fig. 1a) . There was high prevalence of TTS among Caucasian, elderly and females in both cohorts, female (38 to 261/100,000 hospitalizations) and geriatric cancer survivors (24 to 174/100,000 hospitalizations) showed nearly 7-fold increase in TTS in 2017 vs. 2007 (p<0.001). Traditional cardiovascular risk factors, heart failure, chronic pulmonary disease, depression, renal failure and other neurological disorders also increased in the 2017 cohort vs. 2007 cohort. Along with higher rates of atrial tachyarrhythmias (Fig. 1b) , There was nearly 40% (OR 1.39, 95%CI: 1.06-1.82, p=0.016) higher risk of composite MACCE in the 2017 TTS cohort compared to 2007 cohort among cancer survivors Conclusions: Prevalence of TTS among hospitalized cancer survivors increased 8-fold in 2017 compared to 2007. Despite increased awareness about etiopathogenesis and access to improved diagnostic measures, this analysis of TTS cohorts among cancer survivors showed increasing comorbidities with nearly 40% higher risk of composite MACCE across two cohorts selected a decade apart.